拜瑞妥治疗效果

(Rivaroxaban) is a highly selective, oral drug that directly inhibits factor Xa. Xarelto is clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. The mechanism of action of Xarelto is as follows: Inhibiting factor Xa can interrupt the intrinsic and extrinsic pathways of the coagulation cascade, inhibiting thrombin generation and thrombosis. Today we will learn more about the treatment effects of Xarelto.

To explore the efficacy and safety of inferior vena cava filter placement and catheter thrombolysis combined with Xarelto (rivaroxaban) anticoagulant therapy in the treatment of acute lower extremity deep vein thrombosis.

The clinical data of 100 patients with acute lower limb deep vein thrombosis were retrospectively collected and divided into groups according to treatment methods. The patients in the control group received catheter thrombolysis combined with Xarelto tablets, and the patients in the observation group received inferior vena cava filter implantation on the basis of the control group. The treatment effects and complication rates of the two groups were collected and sorted.

Results: Before treatment, after 3 days and 7 days of treatment, there was no statistically significant difference in the circumference difference between the healthy side and the affected side of the lower limbs between the two groups, and the difference in hospitalization time between the two groups was not significant, P>0.05; but after 3 days and 7 days of treatment, the difference in circumference of the limbs in both groups was significantly reduced compared with before treatment, P<0.05; no serious adverse reactions occurred during the treatment in both groups, and no obvious adverse reactions occurred.

Conclusion: The combination of inferior vena cava filter placement, catheter thrombolysis and Xarelto (rivaroxaban) tablets is effective in the treatment of acute lower limb deep vein thrombosis. It helps to promote thrombolysis and shorten hospitalization time. It is highly safe and worthy of promotion.

A domestic study compared 32 patients each in the Xarelto (rivaroxaban) group and the warfarin group. The results showed that the total effective rate of treatment in the Xarelto group was 96.88%, which was higher than the warfarin group; the incidence of adverse reactions in the Xarelto group was 3.13%, which was lower than the warfarin group. These results show that Xarelto has similar efficacy to standard treatment, but with fewer major bleeding events and less intracranial bleeding in critical areas than the standard treatment group.

In addition, some researchers included 80 patients with venous thromboembolism in the study. The results showed that Xarelto (rivaroxaban) has a significant effect in the treatment of patients with venous thromboembolism (P<0.05). It will not inhibit the patient's coagulation function, nor will it have a major impact on the patient's cardiac function. It is highly safe and worthy of recommendation.

The above is the content of the therapeutic effect of (Rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76616.html